The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women

Circulation

Volumn 96, Issue 9, 1997, Pages 2795-2801

  Guetta, Victor ^a   Quyyumi, Arshed A ^a   Prasad, Abhiram ^a   Panza, Julio A ^a   Waclawiw, Myron ^a   Cannon III, Richard O ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Atherosclerosis; Coronary disease; Endothelium; Hormones; Nitric oxide

Indexed keywords

ESTRADIOL; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BLOOD FLOW; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FEMALE; HEART CATHETERIZATION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; VASODILATATION;

EID: 0030664730     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.9.2795     Document Type: Article

References (66)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer EF, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1992;325:756-762.
2. Bush TL, Miller VT. Effects of pharmacologic agents used during menopause: impact on lipids and lipoprotein. In: Mishell D, ed. Menopause: Physiology and Pharmacology. Chicago, Ill: Year Book Medical; 1986:187-208.
3. Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikal V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of plasma lipoproteins. N Engl J Med. 1991;325:1196-1204.
4. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
5. Bush TL, Barrett-Conner E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation. 1987;75:1102-1109.
6. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
7. Miller VM. Modulation of endothelium-dependent and vascular smooth muscle responses by oestrogens. Phlebiology. 1988;224: 19-22.
8. Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, Vita JA. 17β-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation. 1994;89:2251-2259.
9. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994;90;786-791.
10. Gilligan DM, Quyyumi AA, Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 1994;89:2545-2551.
11. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Estradiol acutely attenuates coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
12. Collins P, Rosano GM, Sarrel PM, Ulrich L, Adamopoulos S, Beale CM, McNeill JG, Poole-Wilson PA. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation. 1995;92:24-30.
13. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelium-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol. 1994;73:951-952.
14. Hayashi T, Fukuto JM, Ignarro LJ, Chaudhuri G. Basal release of nitric oxide from aortic rings is greater in female rabbits than male rabbits: implications for atherosclerosis. Proc Natl Acad Sci U S A. 1992;89:11259-11263.
15. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994;91:5212-5216.
16. Chang WC, Nakao J, Orimo H, Murota SI. Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in culture. Biochim Biophys Acta. 1980;619:107-118.
17. Polderman KH, Stehouwer CD, van Kamp GJ, Dekker GA, Verheugt FW, Gooren LJ. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429-432.
18. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women. Lancet. 1995;346:89-90.
19. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
20. Cooke JP, Tsao PS. Cytoprotective effects of nitric oxide. Circulation. 1993;88:2451-2454.
21. Sullivan JM, Vander Zwaag R, Lemp GF, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 1988; 108;358-363.
22. Doucette JW, Corl PD, Payne HM, Flynn AF, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for the intravascular measurement of coronary artery flow velocity. Circulation. 1992;85: 1899-1911.
23. Abraham GE, Odell DW, Swerdloff RS, Hopper K. Simultaneous radioimmunoassay of plasma FSH, LH, progesterone, 17-hydroxyprogesterone, and estradiol-17β during the menstrual cycle. J Clin Endocrinol Metab. 1972;34:312-318.
24. Rees DD, Palmer RM, Hodson HF, Moncada S. A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol. 1989;96:418-424.
25. Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
26. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1980;327:524-526.
27. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol. 1986;250: H1145-H1149.
28. Vanhoutte PM. The endothelium: modulator of vascular smooth muscle tone. N Engl J Med. 1988;319:512-513.
29. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
30. Creager MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86:228-234.
31. Zeiher AM, Drexler H, Wollschlager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothehal dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
32. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
33. Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
34. Chowienczyk PJ, Watts GF, Cockcroft JE, Brett SE, Ritter JM. Sex differences in endothelial function in normal and hypercholesterolemic subjects. Lancet. 1994;334:305-306.
35. Celermajer DS, Sorensen KE, Spiegelhalter JD, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471-476.
36. Quyyumi AA, Dakak B, Andrews NP, Husain S, Arora S, Gilligan DM, Panza JA, Cannon RO. Nitric oxide activity in the human coronary circulation: impact of risk factors for atherosclerosis. J Clin Invest. 1995;1747-1755.
37. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine. Lancet. 1991;328:1546-1550.
38. Dubois-Rande JL, Zelinsky R, Roudot F, Chabrier PE, Castaigne A, Gerschwind A, Adnot S. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous arteries. Am J Cardiol. 1992;70:1269-1275.
39. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90: 1248-1253.
40. Maziere C, Auclair M, Ronveaux M, Salmon S, Santus R, Maziere J. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis. 1991;89;175-182.
41. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17β-estradiol. Metabolism. 1992;41: 1110-1114.
42. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
43. Kim YD, Chen B, Beauregard J, Kouretas P, Thomas G, Farhat YM, Myers AK, Lees DE. 17β-Estradiol prevents dysfunction of canine coronary endothelium and myocardium and reperfusion arrhythmias after brief ischemia/reperfusion. Circulation. 1996;94: 2901-2908.
44. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986;320:454-456.
45. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med. 1994;121:936-941.
46. Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiol and norethisterone acetate. Hypertension. 1995;25:848-853.
47. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 1995;360:291-293.
48. Hayashi T, Yamada K, Esaki T, Kuzuya M, Satake S, Ishikawa T, Hidaka H, Iguchi A. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun. 1995; 214:847-855.
49. Venema RC, Nishida K, Alexander RW, Harrison DG, Murphy TJ. Organization of the bovine gene encoding the endothelial nitric oxide synthase. Biochim Biophys Acta. 1993;1218:413-420.
50. Caulin-Glaser TL, Sessa W, Sarrel P, Bender J. The effect of 17β-estradiol on human endothelial cell nitric oxide production. Circulation. 1994;90(suppl I):I-30. Abstract.
51. Schray-Utz B, Zeiher AM, Busse R. Expression of constitutive NO synthase in cultured endothelial cells is enhanced by 17β-estradiol. Circulation. 1993;88(suppl I):I-80. Abstract.
52. Arnal JF Clamens S, Pechet C, Negre-Salvayre A, Allera C, Girolami JP, Salvayre R, Bayard F. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A. 1996;93:4108-4113.
53. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation. 1996;94:727-733.
54. Kim-Schulze S, McGowan KA, Hubchak SC, Cid MC, Martin MB, Kleinman HK, Greene GL, Schnaper HW. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation. 1996;94:1402-1407.
55. Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson CS. Membrane receptors in GH3/B6 cells are associated with rapid estrogen-induced release of prolactin. Endocrine. 1994;2:813-822.
56. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JM. Nongenomic effects of aldosterone on intracellular calcium in vascular smooth muscle cells. Circ Res. 1995;76:973-979.
57. Farhat MY, Abi-Younes S, Dingaan B, Vargas R, Ramwell PW. Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism. J Pharmacol Exp Ther. 1996;276:652-657.
58. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 1992;131:1305-1312.
59. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K. Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries. J Am Coll Cardiol. 1995;26:807-814.
60. Jiang CW, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
61. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation. 1994;90:1964-1968.
62. De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajarashisth TB, Gimbrone MA, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest. 1995;96:60-68.
63. Peng HB, Rajarashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene expression in vascular endothelial cells. J Biol Chem. 1995;270:17050-17055.
64. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein-1 in cultured human endothelial cells. Circ Res. 1995;76:980-986.
65. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
66. Berliner JA, Nabyab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91: 2488-2496.